MSRCNY RESEARCH

In our state-of-the-art laboratory our team works to reveal the nature of MS at its most basic level

MSRCNY Team

As an academic facility, MSRCNY provides educational and training resources for MS researchers and medical professionals

MSRCNY Goal

Dedicated to developing treatments and a cure for MS

MSRCNY RESEARCH

In our state-of-the-art laboratory our team works to reveal the nature of MS at its most basic level

MSRCNY Team

As an academic facility, MSRCNY provides educational and training resources for MS researchers and medical professionals

MSRCNY Goal

Dedicated to developing treatments and a cure for MS

MSRCNY RESEARCH

In our state-of-the-art laboratory our team works to reveal the nature of MS at its most basic level

MSRCNY Team

As an academic facility, MSRCNY provides educational and training resources for MS researchers and medical professionals

MSRCNY Goal

Dedicated to developing treatments and a cure for MS

Watch Our Story


 

Spotlight

Edward Brydon, PhD
Dr. Brydon's research interests encompass the study of the relationship between viral infection...
Read More

Advance MS Research

Support MSRCNY and our innovative research that leads to treatments that improve the lives of patients.

Latest MSRCNY News

View More

Journal Club: Friday, January 20, 2012

Peggy Bettin (MSRCNY) presented the following article in Journal Club.

Article title: Intrathecally Synthesized IgG in Multiple Sclerosis Cerebrospinal Fluid Recognizes Identical Epitopes Over Time

Reference: X. Yu, M. Brugoon, M. Green, O. Barmina, K. Dennison, Pointon, M. Davis, and D. Gilden. J. Neuroimmunol. (2011), doi:10.1016/j.jneuroim/2011.10.009

Stem Cell Trial Approved!

MSRCNY RECEIVES APPROVAL FOR GROUNDBREAKING STEM CELL TRIAL IN MULTIPLE SCLEROSIS

Landmark Study Targets Repair and Regeneration for MS Patients

New York, NY- November 21, 2011- The Multiple Sclerosis Research Center of New York (MSRCNY) and the International Cellular Medicine Society (ICMS) jointly announced today the ICMS Institutional Review Board’s (IRB) approval of the first study to use autologous brain-like or neural stem cells for multiple sclerosis.